[Topical steroids in the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab].
Coquart
N
N
Karam
A
A
Metges
J-P
JP
Misery
L
L
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D010304:Paronychia / Q000139:chemically induced / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab